Neoadjuvant Treatment of Triple Negative Breast Cancer Patients with Docetaxel and Carboplatin to Assess Anti-tumor Activity

Inclusion Criteria

• Newly diagnosed American Joint Committee on Cancer (AJCC)7 clinical stage II or III breast cancer with complete surgical excision of the breast cancer after neoadjuvant chemotherapy as the treatment goal
• Patients with progesterone receptor positive (PR+) tumors are allowed
• Human epidermal growth factor receptor 2 (HER2) negative by fluorescent in situ hybridization (FISH) or immunohistochemistry (IHC) staining 0 or 1+
• Estrogen receptor (ER) less than Allred score of 3 or less than 1% positive staining cells in the invasive component of the tumor
• Tumor size at least 2 cm in one dimension by clinical or radiographic exam (World Health Organization [WHO] criteria); patients with palpable lymph nodes may be enrolled regardless of tumor size
• Eastern Cooperative Oncology Group (ECOG) performance status =< 2
• Leukocytes >= 3,000/mcL
• Absolute neutrophil count >= 1,500/mcl
• Platelets >= 100,000/mcl
• Serum bilirubin within (or under) normal limits (OR total bilirubin =< 3.0 x institutional upper limit of normal [IULN] with direct bilirubin within normal range in patients with well documented Gilbert syndrome)
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) within (or under) normal limits
• Creatinine clearance >= 30 mL/min/1.73 m^2
• Patients may be pre- or post-menopausal; women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately
• Ability to understand and willingness to sign an Institutional Review Board (IRB) approved written informed consent document (or that of legally authorized representative, if applicable)
• Able to tolerate PET/magnetic resonance imaging (MRI) with intravenous contrast administration and must complete the applicable MRI screening evaluation form

Exclusion Criteria

• Prior systemic therapy for the indexed breast cancer
• A history of other malignancy =< 5 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix
• Patients with bilateral or inflammatory breast cancer
• Currently receiving any other investigational agents
• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel or carboplatin
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant and/or breastfeeding; patient must have a negative serum pregnancy test within 7 days of study entry if premenopausal
• Known human immunodeficiency virus (HIV)-positivity
• Sentinel lymph node biopsy
• Renal insufficiency (glomerular filtration rate (GFR) < 30 mL/min/1.73 m^2) measured within the past 60 days which precludes safe administration of the contrast agent
• On dialysis
• Prior allergic reaction to gadolinium-based magnetic resonance (MR) contrast agents